Back to search results

Dapansutrile for Vascular Activation After Heart Attack

This study is testing an oral medication called dapansutrile in people who have recently had a heart attack (myocardial infarction or MI). Dapansutrile works by targeting inflammation in the body. Researchers want to see if dapansutrile can help reduce the size of plaque (fatty deposits) in the carotid arteries (major blood vessels in your neck) over six months, compared to a placebo (a non-active pill). You might be able to join if you're between 25 and 99 years old, have had a specific type of heart attack, and have plaque in your arteries or a certain thickness in your carotid artery walls. The current recruitment status for this study is unclear.

Study design
This study plans to enroll 60 participants who will be randomly assigned to receive either dapansutrile or a placebo. It is an interventional study, meaning participants will receive a specific treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome measure will be assessed over 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05880355

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Not Yet Recruiting
EARLY_PHASE1Ages 25–99InterventionalTreatment
University of Virginia
~60 participants
Updated 2025-06-04 on ClinicalTrials.gov
What's tested:DapansutrilePlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Remote plaque volume
Measured over 6 months

Conditions

Myocardial Infarction

Explore related trials

Myocardial Infarction

Where it's being run

1 sites across 1 states
Virginia1

Who to contact

Jonathan R Lindner, MD
[email protected]
4342979442
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Acute type I myocardial infarction (NSTEMI or STEMI)
Reperfusion therapy planned or performed within prior 48 hrs
Carotid or femoral artery plaque at baseline, or carotid intima media thickness \>1.5 mm

Exclusion

Type II MI
Failed primary PCI or need for emergent bypass surgery
Severe heart failure (NYHA class IV)
Life-threatening complication of MI (myocardial rupture, ischemic VSD, papillary muscle rupture)
Refractory ventricular arrhythmias
Allergy to dapansutril, OLT177, or drugs in the same class
Co-morbidity limiting 6 month survival
Active malignancy or recent malignancy with any systemic anti-cancer treatment
Active infection
Use of immunosuppressive medications or immunodeficiency disorder
Neutropenia (ANC \<2,000)
Moderate or severe renal impairment (GFR \<30 ml/min)
Recent stroke (within previous 3 months)
Allergy to ultrasound enhancing agents or polyethylene glycol
Pregnancy or breastfeeding

What this trial measures

  • Remote plaque volume6 months

    Carotid artery plaque volume change by ultrasound measured by 3D ultrasound. Outcome units will be cm3 averaged for bilateral carotid arteries.